Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 083: Injectable Cabotegravir vs Oral TDF/FTC for HIV PrEP in MSM and TGW
NCT02720094Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2016; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02720094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720094.